CEO
MucoLife Therapeutics
MucoLife Therapeutics is developing MLT-001, a first-in-class inhaled mucus modulator designed to dissolve airway mucus plugs in patients with COPD and cystic fibrosis. The therapy chelates calcium ions that stabilize the mucin matrix forming plugs, with preclinical data showing 90% mucus plug resolution at a daily dose below 2.5 mg. The company is advancing MLT-001 toward IND-enabling studies and a Phase 1 entry targeted for 2027.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
- Hardware
Updated 4 days ago
Funding
Raised to date
$125KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 3 rounds
MV
SEK 1M · Grant
Announced Nov 2026 · from article date
Disclosed cumulative: $125K
3/3
RoundDateAmountValuationInvestors
Founders
Product
Problem
Airway mucus plugging affects an estimated 50% of moderate-to-severe COPD patients and is independently associated with disease progression, exacerbation risk, and increased mortality. Despite its clinical significance, no approved therapy directly targets the biochemical composition of airway mucus plugs, leaving a critical unmet need in COPD and cystic fibrosis care.
Solution
MucoLife Therapeutics is developing MLT-001, a first-in-class inhaled mucus modulator designed to dissolve pathological mucus plugs obstructing the airways. The therapy works through a novel mechanism of action, chelating the calcium ions that stabilize the MUC5B and MUC5AC mucins forming the mucus plug matrix. Preclinical efficacy of 90% mucus plug resolution has been demonstrated across multiple models at a daily dose below 2.5 mg, with a therapeutic index exceeding 1,000×. The company is also developing a green, dual-use nebulization platform for delivery of MLT-001 across hospital, intensive care, home-care, and emergency preparedness settings.
Target Audience
Primary customers are patients with moderate-to-severe COPD and cystic fibrosis who experience airway obstruction due to mucus plugs, as well as healthcare providers and hospital systems treating muco-obstructive lung diseases.
Features
- First-in-class inhaled peptide that directly dissolves airway mucus plugs by chelating calcium ions stabilizing the MUC5B and MUC5AC mucin matrix
- Demonstrated 90% mucus plug resolution in preclinical models at a daily dose below 2.5 mg with a therapeutic index exceeding 1,000×
- Once-daily inhaled add-on maintenance therapy designed to fit within existing COPD treatment paradigms
- Dual-use nebulization technology optimized for both routine healthcare and crisis-response scenarios
- Scalable manufacturing process being developed in collaboration with a CDMO partner, targeting GMP-compliant production
- Platform potential extending beyond COPD to cystic fibrosis, non-CF bronchiectasis, and asthma